Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Venetoclax + Azacitidine in AML
NCT05431257Phase 2Recruiting
- Sponsor
- Rigshospitalet
- Start
- May 2022
- Primary completion
- Sep 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of venetoclax in acute myeloid leukemia (AML) (2 arms), sponsored by Rigshospitalet. Primary endpoints: Overall Response Rate, Composite Complete Remission Rate and 1 more. Started May 2022; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05431257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05431257.